Quintrio
Home

Stock overview

Immuron Limited American Depositary Shares

IMRN

Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.835 – $0.922
Volume 13,879
Market cap $7M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for IMRN.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for IMRN.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced it has engaged LifeSci Capital as its exclusive financial advisor to evaluate strategic initiatives aimed at maximizing shareholder value. These initiatives may include mergers, acquisitions, licensing, or other strategic transactions. The company will not provide updates unless the Board approves a specific transaction or disclosure is deemed appropriate.

GlobeNewswire Inc.

Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference

Immuron Limited announced that Chief Executive Officer Steven Lydeamore will present virtually at the Emerging Growth Conference on October 28, 2026. The presentation will focus on the company's biopharmaceutical pipeline, including its lead product Travelan® for travelers' diarrhea, IMM-529 for Clostridioides difficile infection, and the ProIBS® distribution agreement in Australia and New Zealand.

GlobeNewswire Inc.

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

Immuron Limited announced FY26 unaudited sales of AUD$7.7 million, up 6% year-over-year, driven by growth in Australia (+10%) and the USA (+7% AUD, +13% USD) for its Travelan® product. Australia's growth was attributed to increased digital marketing, same-store growth, and new retail placements, while US growth benefited from improved Amazon presence and social media initiatives. Canada showed exceptional Q4 growth of 427% on prior comparative period following pipeline fill in FY25, though full-year Canada sales declined 55% due to timing of initial stocking.

GlobeNewswire Inc.

Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Immuron Limited has engaged Pullan Consulting to secure a strategic partnership for IMM-529, its investigational polyclonal antibody treatment for Clostridioides difficile infection (CDI). The company has FDA approval for the IND application and is preparing for Phase 2 clinical trials in Australia. Based on market assessments, IMM-529 could generate projected annual revenues of US$400M if efficacious, with potential partnership deals ranging from US$1-50M upfront plus significant milestone payments and royalties.

GlobeNewswire Inc.

Immuron Double Digit 3Q Sales Growth

Immuron Limited announced Q3 sales of AUD$1.5 million, up 16% year-over-year, driven by growth in Australia (+15%), Canada (+82% quarter-over-quarter), and the USA (+1%). The company attributed growth to increased digital marketing, new retail partnerships, and brand awareness initiatives for its Travelan® product across all regions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.